Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines-Reference-Cited by-同舟云学术

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines

Published:2020-09-23 Issue: Volume:11 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Manson Lisanne E. N.,Swen Jesse J.,Guchelaar Henk-Jan

Funder

Leids Universitair Medisch Centrum

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference109 articles.

1. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir;Agbaji;Nigerian Postgrad. Med. J.,2019

2. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs;Alvestad,2008

3. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children;Amstutz;Clin. Pharmacol. Ther.,2013

4. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population;An;Epilepsy Res.,2010

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of HLA-B*15:02 screening before treatment of epilepsy in Indonesia;Epilepsy & Behavior;2024-06

2. Molecular identification of HLA‐B75 serotype markers by qPCR: A more inclusive pharmacogenetic approach before carbamazepine prescription;Clinical and Translational Science;2024-06

3. Anticipating the side effects of benznidazole: HLA-B*35 and patch test;Enfermedades infecciosas y microbiologia clinica (English ed.);2024-06

4. Anticipating the side effects of benznidazole: HLA-B*35 and patch test;Enfermedades Infecciosas y Microbiología Clínica;2024-05

5. Severe cutaneous adverse reactions;Nature Reviews Disease Primers;2024-04-25